Additional Coverage:
- FDA approves weight loss drug Zepbound for sleep apnea (nbcnews.com)
Zepbound Approved for Sleep Apnea in Obese Adults
The FDA has approved Zepbound for treating obstructive sleep apnea (OSA) in obese adults. This makes Zepbound the first drug specifically approved for OSA, which affects about 39 million Americans.
Zepbound’s Effects on OSA
Zepbound, which contains the same active ingredient as the diabetes drug Mounjaro, has been shown to reduce the frequency of breathing interruptions during sleep. In studies, participants taking Zepbound experienced an average reduction of 25 events per hour compared to those taking a placebo.
Potential for More Insurance Coverage
The expanded approval of Zepbound may increase insurance coverage for weight loss drugs like Zepbound, which have been expensive and often not covered.
Unclear Mechanism of Action
It’s not fully understood how Zepbound helps with OSA. It may be due to weight loss, but researchers believe the active ingredient, tirzepatide, may have other beneficial effects as well.
Comparison to Other Treatments
PAP machines, which provide air pressure to keep the airway open, are the current standard treatment for OSA. While effective, PAP machines can be inconvenient and some patients do not tolerate them well. Zepbound offers an alternative option, either alone or in combination with PAP.
Limitations and Future Research
Zepbound is expensive, has side effects, and requires long-term management. Head-to-head trials are needed to determine its superiority to PAP. Additionally, research is ongoing to explore the effects of Zepbound on other sleep disorders.
Read More About This Story:
- FDA approves weight loss drug Zepbound for sleep apnea (nbcnews.com)